<DOC>
	<DOCNO>NCT02056600</DOCNO>
	<brief_summary>This study evaluate safety/tolerability pharmacokinetics combination gemigliptin 50mg metformin HCl extend release 1000mg comparison component administer healthy male volunteer .</brief_summary>
	<brief_title>BE Study Combinations Gemigliptin 50mg Metformin HCl Extended Release 1000mg Comparison Each Component Administered Alone .</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male adult age 20 45 time screen ThoseSubjects whose BMI measurement screen visit 18 27 kg/m2 Subjects fast plasma glucose ( FPG ) 70125 mg/dL screen visit Subject voluntarily decide participate clinical trial onsented write Subjects past present clinically significant disease hepatic , renal , gastrointestinal , respiratory , musculoskeletal , endocrine , neurological , hematooncological , cardiovascular disorder Subjects past history gastrointestinal disease ( e.g . Crohn 's disease , ulcer , etc . ) surgery ( however , simple appendectomy hernioplasty include ) affect absorption drug Subjects medical history allergic reaction drug include investigational product clinically significant hypersensitivity reaction Subjects history drug abuse Subjects show positive reaction drug may abuse urine drug screen Subjects take investigational product trial within 90 day first administration investigational product Subjects whole blood donation within 60 day component blood donation within 30 day first administration investigational product , transfusion within 30 day first administration Subjects take drug expect effect clinical trial within 14 day date first administration investigational product food expect effect clinical trial within 7 day ( e.g . drink contain caffeine , grapefruit juice , etc . ) Subjects alcohol contain drink 3 time per week within one month screen visit abstain drink complete informed consent form participation study end clinical trial Subjects smoker 10 cigarette per day within recent one month screen visit refrain smoke clinical trial period In vital sign measure sit position screen visit , subject show systolic blood pressure &lt; 90 mmHg &gt; 145 mmHg , diastolic blood pressure &gt; 95 mmHg &lt; 60 mmHg ) , pulse rate &gt; 110 bpm &lt; 40 bpm Subjects show following finding test conduct screening period : In excess 1.5 time upper normal limit ( UNL ) hepatic enzyme ( AST ALT ) value The creatinine clearance calculate CockcroftGault equation 80 mL/min less Positive result serum test ( hepatitis type B test , hepatitis type C test , Human Immunodeficiency Virus ( HIV ) test , syphilis test ) QTc &gt; 450 msec ECG clinically significant abnormal rhythm Subjects consider unsuitable conduct clinical trial reason principal investigator 's discretionary judgment</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>